Form 4: Syndax Pharmaceuticals CEO Exercises Stock Options and Sells Shares
SEC Form 4 Filing
Michael A. Metzger, CEO of Syndax Pharmaceuticals, exercised stock options and sold 6,074 shares of common stock on March 14, 2025.
Summary
- On March 14, 2025, Michael A. Metzger, the CEO of Syndax Pharmaceuticals, exercised stock options to acquire 6,074 shares of common stock at a price of $7.2 per share.
- Simultaneously, Metzger disposed of 6,074 shares.
- Following these transactions, Metzger directly owns 306,195 shares of Syndax Pharmaceuticals.
- The exercised stock options were fully vested.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider trading activity. The sentiment is neutral as it doesn't inherently indicate positive or negative news about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may interpret the CEO's stock activity as a signal, although it's a common practice and doesn't necessarily reflect a change in the company's outlook.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of transaction: Metzger exercised stock options and disposed of shares. |
| 03/17/2025 | Date of signature on the Form 4 filing. |
| 06/01/2025 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.